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Abstract 
At sites of chronic inflammation epithelial cells undergo aberrant DNA methylation that contributes to 
tumorigenesis. Inflammation is associated with an increase in reactive oxygen species (ROS) that cause 
oxidative DNA damage, which has also been linked to epigenetic alterations. We previously 
demonstrated that in response to ROS, mismatch repair (MMR) proteins MSH2 and MSH6 recruit 
epigenetic silencing proteins DNA methyltransferase 1 (DNMT1) and Polycomb repressive complex 2 
(PRC2) members to sites of DNA damage, resulting in transcriptional repression of tumor suppressor 
genes (TSGs). However, it was unclear what signal is unique to ROS that results in the chromatin binding 
of MSH2 and MSH6. Herein, we demonstrate that in response to hydrogen peroxide (H2O2), JAK2 
localizes to the nucleus and interacts with MSH2 and MSH6. Inhibition or knockdown of JAK2 reduces 
the H2O2-induced chromatin interaction of MSH2, MSH6, DNMT1 and PRC2 members, reduces H2O2-
induced global increase in trimethylation of lysine 27 of histone H3 (H3K27me3), and abrogates 
oxidative damage-induced transcriptional repression of candidate TSGs. Moreover, JAK2 mRNA 
expression is associated with CpG island methylator phenotype (CIMP) status in human colorectal cancer. 
Our findings provide novel insight into the connection between kinase activation and epigenetic 
alterations during oxidative damage and inflammation. 
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Introduction 
Chronic inflammation and the associated reactive oxygen species (ROS) play an important role in the 
initiation and progression of many human epithelial cancers (Ding et al. 2017). Aberrant silencing of key 
genes by promoter CpG island DNA hypermethylation and repressive histone modifications occurs in 
many cancers that form at sites of chronic inflammation (Takeshima et al. 2015) (Kondo 2009). Yet, the 
role inflammation plays in initiating these aberrant epigenetic alterations is not completely understood.  
 
Epigenetic alterations cause mitotically heritable changes in gene expression without altering the DNA 
sequence. Aberrant epigenetic alterations promote the progression of cancer by altering the expression 
pattern of key tumor-related genes (Sharma et al. 2010). DNA hypermethylation of promoter CpG islands 
impairs transcription factor binding and thereby decreases gene expression. Post-translational 
modification of histone tails alters gene expression by regulating chromatin structure or recruitment of 
additional histone modifiers and/or readers. During chromatin-based processes such as transcription, 
DNA replication, and DNA repair, chromatin is modified by histone modifying enzymes, chromatin 
remodelers and DNA methyltransferases (Bannister and Kouzarides 2011). For instance, Polycomb 
repressive complex 2 (PRC), which includes Enhancer of zeste homolog 2 (EZH2), Suppressor of zeste 
12 protein homolog (SUZ12), and Embryonic ectoderm development protein (EED), and induces 
trimethylation of histone H3 at Lysine 27 (H3K27me3), contributes to the formation of a repressive 
chromatin state and transient transcriptional inhibition at sites of oxidative DNA damage (O'Hagan et al. 
2011). DNA methyltransferase 1 (DNMT1) methylates newly synthesized DNA during DNA replication 
and participates in maintaining epigenetic silencing of key genes implicated in human cancers (Robert et 
al. 2003).  
 
The recruitment of DNA repair and epigenetic silencing proteins to promoter CpG islands in response to 
ROS may be important for initiating aberrant DNA methylation. Guanine residues in DNA are a primary 
target for ROS during inflammation, with 8-oxo-G being the most abundant form of oxidative damage 
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(Ba et al. 2014). Due to high guanine content, promoter CpG islands are hotspots for 8-oxo-G and 
therefore oxidative DNA damage. 8-oxo-G lesions are repaired by base excision repair (David et al. 2007) 
and non-canonical MMR (Zlatanou et al. 2011) pathways. We have shown that MMR proteins MSH2 and 
MSH6 have an increase in affinity for chromatin after 30 min of H2O2 treatment (Ding et al. 2016). 
MSH2 and MSH6 recruit epigenetic silencing proteins DNMT1 and EZH2 to sites of oxidative damage 
through a protein-protein interaction-dependent mechanism (Ding et al. 2016). In vitro and in vivo, we 
have demonstrated that the recruitment of DNMT1 and EZH2 to sites of oxidative DNA damage results in 
increased H3K27me3 deposition in the promoters of candidate TSGs that is associated with decreased 
gene expression (O'Hagan et al. 2011; Maiuri et al. 2017). In vivo, this early recruitment to sites of 
oxidative damage results in sustained DNA hypermethylation of the TSGs’ promoter CpG islands in 
tumors that form as a result of chronic inflammation  (Maiuri et al. 2017). These findings are congruent 
with the knowledge that cancer-specific aberrant gains in DNA methylation tend to occur at gene 
promoters enriched for H3K27me3 (Schlesinger et al. 2007; Rose and Klose 2014). However, the 
upstream mechanism for increased affinity of MSH2 and MSH6 for sites of oxidative DNA damage is 
still unclear.  
 
The tyrosine kinase, Janus kinase 2 (JAK2), plays important roles during the inflammatory response 
(Boland et al. 2014), carcinogenesis (Du et al. 2012), DNA damage and repair (Gloc et al. 2002; Scott and 
Rebel 2012), and may regulate epigenetic alterations (Dawson et al. 2009). Canonical activation of JAK2 
occurs in response to binding of various ligands such as interleukin-6 (IL-6) and growth hormones to the 
receptor to which JAK2 is bound. In this canonical response, activated JAK2 phosphorylates its 
downstream effector-Signal transducer and activator of transcription 3 (STAT3), which initiates 
transcription of genes associated with cell proliferation, differentiation and oncogenesis (Wang and Sun 
2014). In contrast, ROS induces JAK2 signaling activation in a ligand-independent fashion (Duan et al. 
2013). In addition, ROS reduces STAT3 binding to its canonical binding targets such as consensus serum-
inducible elements (SIE) and diminishes IL-6-mediated gene transcription (Li et al. 2010; Scott and Rebel 
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2012; Sobotta et al. 2015). These results suggest gene activation by the canonical JAK2 pathway and by 
the ROS-mediated pathway may be different. Mutant JAK2, which is constitutively active, also has non-
canonical roles. Mutant JAK2 V617F can be localized in the nucleus, directly phosphorylate histone H3 
at Y41, and regulate gene expression independently of ligand-activation or STAT3-interaction (Dawson 
et al. 2009).  
 
Herein, we connect JAK2 to the MMR and epigenetic response to oxidative damage. We uniquely 
demonstrate that active wildtype JAK2 translocates to the nucleus in response to oxidative damage and 
that nuclear JAK2 plays a critical role in regulating MSH2, MSH6, DNMT1 and EZH2 chromatin binding, 
and global levels of H3K27me3. We further show that JAK2 is important for oxidative damage-induced 
transcriptional repression of candidate TSGs in colon cancer cells. Understanding the connection between 
JAK2, MSH2, MSH6, and epigenetic alterations will provide key insight into how aberrant epigenetic 
alterations are initiated during chronic inflammation. 
 
Materials and methods 
Cell culture and treatments 
NCCIT and SW480 cells were purchased from American Tissue Type Culture Collection (ATCC) and 
maintained in RPMI 1640 and McCoy’s 5A media (Corning, PA), respectively with 10% fetal bovine 
serum (Gibco, MA). H2O2 treatment was performed as previously described (Ding et al. 2016). 
Tyrphostin AG490 (Sigma, MO, T3434-5MG) was dissolved in DMSO (Sigma, MO) and further diluted 
before adding it to the media. Cells were treated with 100 μM Tyrphostin AG490 for 6 hours prior to 
H2O2 exposure. BMS-911543 (Biovision, CA, 2630-5) was dissolved in DMSO (Sigma, MO) and further 
diluted before adding it to the media. Cells were treated with 2.2 nM BMS-911543 for 6 hours prior to 
H2O2 exposure.  
 
shRNA knockdown 
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For shRNA knockdown of JAK2 and Non-target (NT), cells were infected with lentiviral particles for 96 
hours with puromycin (Sigma, MO) selection before collection following the manufacturer’s protocol 
(Sigma, MO). JAK2 (Sigma, MO, SHCLNG-NM_004972, TRCN000002181) and TRC2 (NT) (Sigma, 
MO, SHC201) were expressed using lentiviral particles following the lentiviral shRNA knockdown 
protocol from The RNAi Consortium Broad Institute.  
 
Antibodies 
For Co-IP of endogenous proteins, anti-JAK2 (Millipore, 06-255-I¸1:100), anti-MSH2 (Cell Signaling 
Technology (CST, MA), 2017S, 1:200), anti-MSH6 (Becton Dickinson (BD, NJ), 610918, 1:100), anti-
EZH2 (CST, MA, 5246T, 1:200) antibodies were used. For western blot, anti-JAK2 (Millipore, 06-255-I, 
1:1000 and Abcam, CA, ab108596, 1:1000 ), anti-p-JAK2 (Y1007/1008, 1:1000) (Millipore, MA, 07-
606), anti-p-STAT3 (Y705) (CST, MA, 9145S, 1:1000), anti-LaminB (Santa Cruz (SC, CA), sc-6216, 
1:1000), anti-GAPDH (CST, MA, 5174, 1:1000), anti-MSH2 (CST, MA, 2017S, 1:1000), anti-MSH6 
(BD, 610918, 1:1000), anti-DNMT1 (Sigma, MO, D4692, 1:1000), anti-EZH2 (CST, MA, 3147S, 
1:1000), anti-STAT3 (CST, MA, 9139, 1:1000), anti-H2AX (CST, MA, 9718, 1:1000), anti-H3K27me3 
(CST, MA, 9733, 1:1000), anti-H3 (CST, MA, 9751, 1:3000), anti-EZH2 (CST, MA, 3147S, 1:1000), 
anti-SUZ12 (CST, MA, 3737, 1:1000), anti-EED (Sigma, MO, GW10896A, 1:500) antibodies were used. 
For immunofluorescence, anti-JAK2 (Abcam, CA, ab108596, 1:100), anti-DNMT1 (SC, CA, sc-20701, 
1:100), anti-H2AX (Millipore, NJ, 05-636, 1:100), secondary Alexa Conjugate (CST, MA, mouse 8890, 
1:500 and rabbit 8889, 1:1000) were used.  
 
Nuclear/cytoplasmic extraction, chromatin affinity assay, and whole cell isolation 
These assays were performed as previously described (Ding et al. 2016). Band densitometry for western 
blots were measured by Image J software (NIH). Band densitometry were first normalized to LaminB or 
H3 and then relative densitometry of proteins across treatments was normalized to the untreated condition. 
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Immunofluorescence and Co-IP 
Immunofluorescence was performed with or without preextraction buffer as indicated. 
Immunofluorescence and Nuclear Co-IP were performed as previously described (Ding et al. 2016). 
Obtained fluorescence images were subjected to digital processing and background subtraction by Adobe 
Photoshop CS with identical conditions for each treatment group.  
 
Histone methyltransferase activity assay (H3K27) 
Nuclear extraction was performed followed by histone methyltransferase activity ELISA assay according 
to the manufacturer’s protocol (EpiGenTEK, OP-0002-1 and P-3005-48). 
 
qPCR (quantitative Polymerase Chain Reaction) 
Total RNA was first isolated (Qiagen, 74104) and reverse transcribed according to the manufacturer’s 
protocol (Thermo, K1642). cDNA was used for qPCR analysis with gene-specific primers and the 
reactions were detected using a FastStart Essential DNA Green Master (Roche, CA, 06402712001). The 
expression of mRNA was normalized to glyceraldehyde 3-phosphate dehydrogenase (GAPDH) 
expression. (GAPDH; △Cq = target mRNA Cq – GAPDH Cq). The individual primers used were listed 
below: 
MLH1, forward, AAGCTCCTGGGCTCCAATTC 
MLH1, reverse, CGAGGTCAGACTTGTTGTGGA  
CDH1, forward, ATCCCACCACGTACAAGGGT  
CDH1, reverse, GTGTATACAGCCTCCCACGC  
GAPDH, forward, GAAGGTCGGAGTCAACGGATTT  
GAPDH, reverse, ATGGGTGGAATCATATTGGAC 
 
Statistical analysis 
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Relative densitometry, cell foci and qPCR data are presented as the mean ± standard error (SEM). These 
data are evaluated by one-way ANOVA with multiple comparisons and considered statistically significant 
with a p-value < 0.05. The number of replicates for each experiment is included in figure legends.  
 
Results 
Oxidative damage induces catalytic activity-dependent JAK2 nuclear translocation.  
In the canonical JAK2-STAT3 pathway, JAK2 becomes active, is autophosphorylated (p-JAK2 at 
Y1007/1008) and recruits STAT3 for phosphorylation (p-STAT3) in response to IL-6 stimulation (Wang 
and Sun 2014). While p-STAT3 translocates to the nucleus upon IL-6 treatment, activated JAK2 is 
retained in the cytoplasm by remaining bound to its receptor.  To test if H2O2 changes the subcellular 
localization of endogenous JAK2, nuclear and cytoplasmic fractions were isolated from untreated or 
treated human embryonic carcinoma (NCCIT) cells. In contrast to IL-6, H2O2 treatment increases JAK2 
protein levels in the nuclear fraction and decreases levels in the cytoplasmic fraction, as compared to 
untreated cells (Figure 1A). To confirm these results, experiments were repeated with a different JAK2 
antibody. We demonstrated that both antibodies detect a band at the molecular weight of 131 kDa in 
whole cell extracts from non-target knockdown (NT) NCCIT cells and this band is reduced in JAK2 
knockdown cells with or without H2O2 treatment, confirming the specificity of the two JAK2 antibodies 
(Supplementary Figure 1A). To determine if JAK2 catalytic activity is important for JAK2 nuclear 
translocation, cells were treated with the JAK2 inhibitor Tyrphostin AG490 6 hours prior to H2O2 
treatment and nuclear extractions were performed. Inhibiting JAK2 activity significantly reduces JAK2 
and p-JAK2 nuclear localization (Figure 1B). In confirmation of the efficacy of the inhibitor, AG490 
treatment reduces IL-6-induced levels of p-STAT3 (Figure 1B). Although Tyrphostin AG490 is a potent 
JAK2 inhibitor, it also nonspecifically inhibits other protein tyrosine kinases (Sayyah and Sayeski 2009). 
Therefore, we used BMS-911543, a highly selective JAK2 inhibitor, to further validate our findings. At a 
nanomolar concentration BMS-911543 only inhibits the activity of JAK2 but not JAK1, JAK3 or SET-2 
(Wan et al. 2015). Inhibition of JAK2 by pretreatment with 2.2 nM BMS-911543 also reduces the H2O2-
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induced nuclear localization of JAK2 (Figure 1C). To further confirm JAK2 nuclear translocation, JAK2 
subcellular localization was assessed by immunofluorescence. Low levels of JAK2 are present throughout 
the cell in untreated cells and cells treated with IL-6, whereas nuclear staining is detected after H2O2 
treatment (Figure 1D). Knockdown of JAK2 reduces oxidative damage-induced JAK2 signal in nuclei, 
suggesting this nuclear signal is JAK2 specific (Supplementary Figure 1B). In confirmation of our 
western blot findings, inhibiting JAK2 catalytic activity with Tyrphostin AG490 abrogates the oxidative 
damage-induced nuclear localization of JAK2, suggesting JAK2 nuclear localization in response to 
oxidative damage is dependent on its catalytic activity.  
 
Inhibition of JAK2 alters oxidative damage-induced chromatin binding of MSH6, MSH2 and 
DNMT1 
Previously, it was demonstrated that MSH2 and MSH6 are predominantly localized in the cytoplasm 
basally but translocate into the nucleus and interact with DNMT1 in response to oxidative damage (Ding 
et al. 2016). Since we observed that oxidative damage also induces JAK2 nuclear translocation (Figure 
1A), we initially hypothesized that nuclear localization of MSH2 and MSH6 after oxidative damage may 
be dependent on JAK2. However, as demonstrated by protein levels in nuclear fractions (Supplementary 
Figure 2A) from BMS911543 or Tyrphostin AG490 treated cells and nuclear inputs used for co-
immunoprecipitation (co-IP) after Tyrphostin AG490 treatment (Supplementary Figure 3A and 3B), 
JAK2 inhibition does not affect nuclear levels of MSH2, MSH6 or DNMT1 basally or in response to 
oxidative damage. By using a chromatin affinity assay that includes a high concentration salt buffer wash, 
we previously demonstrated that oxidative damage increases the affinity of MSH2, MSH6 and DNMT1 
for chromatin (Ding et al. 2016). In response to H2O2 treatment, JAK2 also has increased affinity for 
chromatin (Figure 2A). Importantly, inhibition of JAK2 by Tyrphostin AG490 reduces the H2O2-induced 
increase in affinity of MSH6, DNMT1 and JAK2 for chromatin. JAK2 inhibition prevents a statistically 
significant increase in affinity of MSH2 for chromatin after H2O2 treatment when comparing untreated 
and H2O2-treated JAK2-inhibited samples. However, JAK2 inhibition does not significantly reduce the 
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increase in affinity of MSH2 for chromatin in response to H2O2 treatment as compared with H2O2 
treatment alone (Figure 2A). This finding suggests that there may be an additional mechanism for H2O2-
induced MSH2 chromatin binding, possibly through its interaction with MSH3 as part of MutS, which 
we have demonstrated occurs basally and after oxidative damage (Ding et al. 2016). The total cellular 
levels of MSH2, MSH6 and DNMT1 are not affected by Tyrphostin AG490 or H2O2 treatment (Figure 
2A). Moreover, inhibition of JAK2 by Tyrphostin AG490 increases the level of H2AX basally and after 
oxidative damage (Figure 2A), consistent with a previous report that JAK2 activation causes an increase 
in homologous recombination (Gloc et al. 2002). Consistent with the effect of Tyrphostin AG490, 
inhibition of JAK2 by BMS-911543 reduces the H2O2-induced increase in affinity of MSH6, MSH2, 
DNMT1 and JAK2 for chromatin (Figure 2B). BMS-911543 treatment reduces oxidative damage-induced 
levels of p-STAT3 (Figure 2B), confirming the efficacy of the inhibitor. There is a trend for an increase of 
H2AX levels in response to BMS911543 treatment basally and after oxidative damage, but this change is 
not significant (Figure 2B). To confirm these findings, binding of MSH2, MSH6 and DNMT1 to 
chromatin following knockdown of JAK2 by lentiviral shRNA was analyzed. Knockdown of JAK2 
reduces oxidative damage-induced chromatin binding of MSH6 and DNMT1 without affecting total 
protein levels of MSH6 or DNMT1 (Figure 2C). Again, there is a trend for reduction in affinity for 
MSH2, but this change is not significant (Figure 2C). Consistent with our previous results (Ding et al. 
2016), knockdown of MSH6 reduces oxidative damage-induced chromatin interaction of MSH6 and 
DNMT1 but does not affect total protein level of DNMT1 (Figure 2C).  
 
Immunofluorescence can also be used to interrogate DNMT1’s response to oxidative damage because 
oxidative damage induces DNMT1 foci that co-localize with the DNA damage marker H2AX (Ding et 
al. 2016) (Supplementary Figure 2B). Inhibition or knockdown of JAK2 abrogates the formation of 
oxidative damage-induced DNMT1 foci and the co-localization between DNMT1 and H2AX 
(Supplementary Figure 2B and 2C). Consistent with the western blot results (Figure 2A and 2B), 
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inhibition or knockdown of JAK2 elevates levels of H2AX basally and after oxidative damage in 
immunofluorescence analysis (Supplementary Figure 2B and 2C).  
 
Besides JAK2 oxidative damage also activates several other protein kinases such as Protein kinase C 
(PKC), Protein kinase B (PKB or AKT), Jun N-terminal kinases (JNK), mitogen-activated protein 
kinase (MAPK) (Martindale and Holbrook 2002). Treatment of cells with inhibitors of these kinases 
(Staurosporine (PKCi), LY294002 (PI3K/AKTi), SP600125 (JNKi), SB203580 (MAPKi)) at doses that 
reduce known downstream targets does not reduce oxidative damage-induced MSH2, MSH6 or DNMT1 
chromatin binding (data not shown), suggesting these protein kinases do not regulate the chromatin 
binding of MSH2, MSH6 and DNMT1 in response to oxidative damage.  
 
JAK2 interacts with MSH2 and MSH6 in the nucleus in response to H2O2 treatment 
In response to H2O2 treatment, MSH6, MSH2, DNMT1 and JAK2 concordantly have increased affinity 
for chromatin (Figure 2A). We hypothesized that nuclear JAK2 interacts with one or multiple of these 
proteins and therefore cytoplasmic and nuclear Co-IPs were performed to study the protein-protein 
interactions in different cellular compartments. Previously we have demonstrated that MSH2 and MSH6 
primarily localize in the cytoplasm in the basal state in NCCIT cells (Ding et al. 2016). Here, we 
demonstrate that MSH2 interacts with JAK2 and MSH6 in the untreated state in the cytoplasm (Figure 
3A). In response to oxidative damage, the interaction of MSH2 with MSH6 in the cytoplasm is reduced 
and there is no detectable JAK2 in the cytoplasm. (Figure 3A). In response to H2O2 treatment, levels of 
MSH2, MSH6 and JAK2 in the nuclear input fraction are increased consistent with their nuclear 
translocation (Figure 3B-3D); whereas DNMT1and EZH2 are unchanged. JAK2 interacts with MSH2 and 
MSH6 in nuclear fractions in response to H2O2, while no interaction is detected in untreated cells (Figure 
3B). No interaction is detected between nuclear JAK2 and epigenetic proteins, including DNMT1, EZH2, 
SUZ12 or EED2 basally or in response to H2O2 (Figure 3B and data not shown). Nuclear Co-IPs using 
antibodies against MSH2 and MSH6 confirm their interaction with JAK2 in the nucleus after H2O2 
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treatment (Figure 3C and 3D). Together, these findings demonstrate that MSH2 interacts with JAK2 
basally in the cytoplasm and oxidative damage induces the nuclear translocation of MSH2, MSH6 and 
JAK2 resulting in their interaction in the nucleus.  
 
Inhibition of JAK2 alters the PRC2 response to oxidative damage. 
Previously, we have demonstrated that oxidative damage induces the DNMT1-dependent interaction of 
MSH2 and MSH6 with PRC2 members, EZH2, SUZ12, and EED2 (O'Hagan et al. 2011) (Ding et al. 
2016). Because inhibition of JAK2 alters the interaction of DNMT1 with chromatin, it may also affect the 
chromatin affinity of PRC2 members. Interestingly, although H2O2 alone does not increase the affinity of 
EZH2 and EED for chromatin, inhibition of JAK2 by Tyrphostin AG490 or BMS-911543 significantly 
reduces EZH2 and EED2 chromatin affinity after H2O2 treatment (Figure 4A and 4B). After H2O2 
treatment, there is a trend for reduction in affinity for SUZ12 with inhibition of JAK2 by either 
Tyrphostin AG490 or BMS-911543, but the effect of Tyrphostin AG490 is not significant (Figure 4A and 
4B). These results were further validated in the SW480 colon cancer cell line (Supplementary Figure 4A). 
To test if JAK2 alters the protein-protein interactions between MSH6, DNMT1 and PRC2, nuclear Co-IPs 
were performed using antibodies against MSH6 or EZH2 in cells where JAK2 was inhibited followed by 
30 min H2O2 treatment. JAK2 inhibition does not alter the oxidative damage-induced interaction of 
MSH6, DNMT1, and PRC2 (Supplementary Figure 3A and 3B).  
 
The finding that JAK2 alters the chromatin interaction of PRC2 members in response to oxidative damage 
suggests a potential functional role for JAK2 in regulating the level of H3K27me3 after oxidative 
damage. As previously demonstrated, 3 hours after H2O2 treatment, there is a global increase of 
H3K27me3 (Niu et al. 2015). Knockdown of JAK2 significantly reduces oxidative damage-induced 
H3K27me3 levels (Figure 4C). H2O2 can alter the catalytic activity of enzymes (Rhee et al. 2000) and 
EZH2’s activity can be altered by post-translational modifications (Karantanos and Boussiotis 2016). 
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However, neither JAK2 knockdown nor H2O2 treatment alters the H3K27me3 histone methyltransferase 
activity in cellular lysates compared to basal NT cells (Supplementary Figure 4B).  
 
Oxidative damage causes a transient reduction in transcription of CpG island containing genes, including 
the TSGs CDH1 (Cadherin1 or E-cadherin) and MLH1 (MutL homolog 1) that commonly undergo gene 
silencing and promoter CpG island hypermethylation in colorectal cancer (Wheeler et al. 2001; Li et al. 
2013). This reduction in transcription is dependent on the MSH2/6-mediated recruitment of epigenetic 
proteins to chromatin (Ding et al. 2016). Consistent with these results, H2O2 treatment leads to a reduction 
in gene expression of CDH1 and MLH1 in SW480 cells and JAK2 inhibition significantly abrogates this 
reduction in transcription (Figure 4D). Altogether, these findings suggest that JAK2 regulates oxidative 
damage-induced global changes in H3K27me3 and transcription of candidate TSGs through altering the 
interaction of MSH2/MSH6, DNMT1 and PRC2 member proteins with chromatin.  
 
JAK2 expression is associated with CIMP in human colorectal cancer.  
Cancer-specific aberrant gains in DNA methylation tend to occur at gene promoters enriched for 
H3K27me3 (Schlesinger et al. 2007; Rose and Klose 2014). In humans, tumors bearing a high frequency 
of occurrence of aberrant promoter CpG island DNA hypermethylation are defined as CIMP-high (CIMP-
H), whereas tumors bearing lower frequency or minimal CpG island hypermethylation are referred to as 
CIMP-L or non-CIMP, respectively. CIMP positive status is associated with poor prognosis and worse 
treatment outcome than non-CIMP status in colorectal cancer patients (Van Rijnsoever et al. 2003). 
Having demonstrated JAK2 is important for the recruitment of DNMT1 to sites of damage and global 
induction of H3K27me3, we next examined if JAK2 is associated with aberrant DNA hypermethylation 
in colorectal cancer, using CIMP status as a surrogate marker for promoter CpG island hypermethylation. 
In JAK2 RNA-seq data and CIMP status obtained from the TCGA colorectal cancer database ( The 
Cancer Genome Atlas,  COADREAD) (The Cancer Genome Atlas Network 2012), CIMP-H status 
correlates with higher expression of JAK2 mRNA, whereas CIMP-L or non-CIMP (Cluster 3 and 4) 
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cancers have lower gene expression of JAK2 (Figure 5), suggesting JAK2 expression is closely associated 
with promoter CpG island methylation in colorectal cancer.  
 
Discussion 
Recent studies demonstrate that kinases activated by cellular stress can alter the function of epigenetic 
proteins, leading to increased epigenetic regulation in cells (Cha et al. 2005; Kim et al. 2013). In the 
present study, we link the oxidative damage-induced activation and nuclear localization of JAK2 to the 
enrichment of MMR and epigenetic silencing proteins on damaged chromatin. This response is associated 
with changes in global levels of H3K27me3, and transcriptional repression of candidate TSGs in cancer. 
Furthermore, JAK2 mRNA expression is closely associated with CIMP-H status in colorectal cancer. 
While it is well known that constitutive activation of JAK2 can induce neoplastic transformation and 
cancer progression by activating downstream STAT proteins and promoting oncogenic transcription in 
hematopoietic malignancies (Vainchenker et al. 2008), much less is known regarding non-canonical roles 
of nuclear JAK2 in solid tumors. The role of JAK2 activity and non-canonical nuclear localization in the 
MMR and epigenetic responses to oxidative damage potentially links JAK2 to tumor progression in a 
novel way. 
 
JAK2 is canonically studied as a cytoplasmic protein that is bound to a receptor and transmits information 
in response to ligand binding to the receptor to effect downstream gene transcription. In this study, we 
identified a noncanonical role of JAK2 in response to oxidative damage in human cells that is uncoupled 
from its role in the classic, ligand-dependent pathway. We demonstrate that in response to oxidative 
damage, JAK2 can localize to the nucleus, while activation of JAK2 in a canonical manner by IL-6 
treatment does not induce such a change. This finding indicates that oxidative damage may employ 
different mechanisms from IL-6 to activate JAK2, possibly through oxidizing and inhibiting JAK2’s 
negative regulator-protein tyrosine phosphatases (PTPs), including Cluster of differentiation 45 (CD45) 
and Src homology region 2 domain-containing phosphatase-1 (SHP1) (Oh et al. 2009). JAK2 is basally 
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inhibited and dephosphorylated at Y1007/1008 by PTPs (Li et al. 2015). ROS induce thiol oxidation in 
the catalytic sites of PTPs and this modification permits release of JAK2 from the PTPs, resulting in 
activation of JAK2 (Knobler and Elson 2014) (Oh et al. 2009). In line with these findings, we connect 
JAK2 nuclear translocation to its activity by demonstrating that inhibition of JAK2 induces 
dephosphorylation of JAK2 at Y1007/1008 and reduces oxidative damage-induced nuclear localization of 
JAK2. Further supporting the role of JAK2 phosphorylation in mediating JAK2 nuclear translocation, the 
JAK2 kinase-dead mutant K882E shows basally low nuclear localization signal, whereas the 
constitutively active JAK2 V617F has high nuclear localization signal (Sedek and Strous 2013).  
 
Epigenetic proteins are involved in the DNA damage response and it is hypothesized that DNA repair 
pathways recruit epigenetic proteins to assist in the DNA repair process. The role of epigenetic proteins in 
DNA repair has been described by the “access-repair-restore” model (Green and Almouzni 2002; Ding et 
al. 2017). In response to damage, “active” chromatin modifiers such as histone acetyltransferases (HATs) 
and chromatin remodeling complexes are first recruited to the sites of DNA damage to “open” local 
chromatin structure allowing DNA repair proteins to gain access. Once DNA repair proteins access DNA, 
“repressive” chromatin modifiers such as histone deacetylases (HDACs) are recruited to “close” the 
chromatin and repress transcriptional activity. Finally, chromatin is restored back to its original state 
when repair is completed (Ding et al. 2017). In response to oxidative DNA damage, we demonstrated that 
(1) JAK2 is recruited to chromatin, (2) JAK2 interacts with MSH2 and MSH6 in the nucleus,  and (3) 
inhibiting JAK2 alters the chromatin interaction of MSH2, MSH6, DNMT1, and PRC2 members. JAK2 
inhibition or knockdown does not alter oxidative damage-induced nuclear localization of MSH2 and 
MSH6 suggesting that the increased chromatin association of MSH2 and MSH6 in response to oxidative 
damage is not through their increased nuclear localization. Based on these results, we hypothesize that in 
response to oxidative damage, JAK2 recruits MSH2 and MSH6 to promoter CpG islands that contain 
clustered oxidative damage as a result of preferential oxidative damage of guanines. Previous studies 
demonstrated that constitutively active mutant JAK2 acts as an “active” chromatin modifier, which can 
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directly interact and phosphorylate histone H3 at Y41 (H3Y41ph) to promote downstream transcription 
(Dawson et al. 2009). The H3Y41ph mark is associated with transcriptional activity and is primarily 
present at promoter transcription start sites (TSS) of active genes. Importantly, inhibition of JAK2 
significantly reduces H3Y41ph at the TSS of genes (Dawson et al. 2012). We hypothesize that in 
response to oxidative damage, JAK2 is recruited to chromatin to mediate chromatin-based changes at 
damaged promoters and these changes facilitate DNA repair. The association of JAK2 with active 
chromatin may first open up local chromatin structure to allow MSH2 and MSH6 to gain access to 
clustered oxidative DNA damage. After accessing the damage, MSH2 and MSH6 recruit “repressive” 
epigenetic proteins including DNMT1 and PRC2 members to sites of damage. This recruitment results in 
a transient reduction in transcription so that transcription does not interfere with the DNA repair (Ding et 
al 2016). An alternative hypothesis is that JAK2 may regulate the chromatin interaction of MSH2 and 
MSH6 through phosphorylation of MSH2 and/or MSH6. There are known phosphorylation events that 
alter the MMR response to DNA damage. For example, MSH2 can be phosphorylated by the tyrosine 
kinase NPM-ALK in a manner that inhibits dimerization of MSH2 with MSH6 (Bone et al. 2015). We 
immunoprecipitated MSH2 and MSH6 from nuclear extracts from both untreated and H2O2 treated 
NCCIT cells and performed LC-MS/MS tandem mass spectrometry in an effort to identify tyrosine 
phosphorylation modifications on MSH2 and MSH6, but were unable to detect these modifications. 
Because of the known difficulty in detecting tyrosine phosphorylation on large proteins by mass 
spectrometry, we cannot rule out the possibility that JAK2’s regulation of MSH2 and MSH6 is through a 
phosphorylation event. Further studies on how JAK2 increases the affinity of MSH2 and MSH6 for 
chromatin in response to oxidative damage are needed.  
 
Our findings suggest one potential mechanism for the initiation of abnormal silencing of TSGs during 
tumorigenesis. We provide a novel link between JAK2, recruitment of repressive proteins and transient 
loss of gene expression in response to oxidative damage. JAK2 signaling is well known for its function 
upstream of transcriptional activation of genes that are responsible for growth and proliferation. However, 
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the findings presented here uniquely suggest that oxidative damage-induced nuclear JAK2 regulates 
chromatin enrichment of DNA repair proteins, epigenetic silencing proteins, and H3K27me3, thereby 
facilitating repression of candidate TSGs. JAK2 may also be linked to aberrant promoter CpG island 
DNA hypermethylation seen in human cancers. The JAK2-dependency of enhanced binding of DNMT1 
to chromatin in response to oxidative damage, suggests that JAK2 is important for aberrant DNMT1 
targeting during DNA damage. Recruitment of DNMT1 to sites of damage can result in sustained, 
aberrant DNA methylation of gene promoters both in vitro and in vivo (O'Hagan et al. 2008) (Maiuri et al. 
2017). In line with these results, we demonstrate that JAK2 mRNA expression is associated with CIMP 
status in colorectal cancer. Together these results suggest JAK2 may participate in the initiation of 
aberrant DNA methylation during chronic inflammation.  
 
Epigenetic therapy such as treatment with DNMT inhibitors azacytidine and decitabine is currently 
recommended to treat high risk myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML). 
DNMT inhibitors are also currently being used to treat solid tumors in clinical trials. Despite their 
promising clinical future, success of these agents may depend on the durability of the DNA demethylation 
induced by them (Kagey et al. 2010). Azacytidine treatment of cells in vitro effectively reverses DNA 
hypermethylation. However, after removing azacytidine from the cells, genes reaccumulate promoter 
DNA hypermethylation over time (McGarvey et al. 2006). This result is possibly due to the fact that 
azacytidine only alters DNA methylation but does not alter the low levels of repressive chromatin marks, 
including H3K27me3 that are present at these promoters (McGarvey et al. 2006). This may be critical, as 
retention of H3K27me3 is known to recruit DNMTs and induce DNA methylation (McGarvey et al. 
2006). Inhibition of JAK2 by Tyrphostin AG490 or BMS-911543 results in reduced binding of DNMT1 
and PRC2 members to chromatin, which may result in reduction of H3K27me3 deposition on genes 
during inflammation and carcinogenesis and reduce their resilencing after azacytidine treatment is 
stopped. However, whether JAK2 inhibition affects re-silencing of aberrantly DNA hypermethylated 
genes requires further study and validation. In addition, inhibiting JAK2 by BMS-911543 is shown to be 
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safe, well tolerated in human, and this inhibitor is currently in clinical trials for treatment of myelofibrosis 
(Roberts et al. 2013). While further studies are required, nuclear JAK2 may be a potential target for the 
development of additional therapeutics for inflammation-driven cancers. 
 
In summary, we demonstrate that in response to oxidative damage, JAK2 is activated and translocates 
into the nucleus where it plays a key role in regulating MSH2 and MSH6 binding to damaged chromatin.  
Through its regulation of MSH2 and MSH6, JAK2 also affects oxidative-damage induced increases in 
DNMT1 and EZH2 chromatin affinity, chromatin modifications and changes in gene expression of 
candidate TSGs. Furthermore, we demonstrate that JAK2 mRNA expression is closely correlated with 
CIMP status in human colorectal cancer. 
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Figure Legends 
Figure 1. Oxidative damage induces catalytic activity-dependent JAK2 nuclear localization. 
(A) Nuclear extractions were performed using NCCIT cells untreated or treated with 2 mM H2O2 for 30 
min or IL-6 (10 ng/ml) for 10 min. LaminB and GAPDH are nuclear and cytoplasmic controls, 
respectively. The data presented are from one representative experiment of two biological replicates. (B) 
Nuclear extractions were performed using NCCIT cells untreated or treated with 100 M Tyrphostin 
AG490 for 6 hours followed by 2 mM H2O2 for 30 min or 10 ng/ml IL-6 treatment for 10 min. p-STAT3 
serves as a control for treatments. Relative densitometry data are displayed as meanSEM for each 
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treatment condition for JAK2 and p-JAK2 (n = 3). **P < 0.01, “ns” indicates not significant, P > 0.05. (C) 
Nuclear fractions were prepared from NCCIT cells untreated or treated with 2.2 nM BMS-911543 for 6 
hours followed by 30 min, 2 mM H2O2 treatment. Relative densitometry data are displayed as meanSEM 
for each treatment condition (n = 3). *P < 0.05, “ns” indicates not significant, P > 0.05 (D) NCCIT cells 
were treated as in B followed by immunofluorescence analysis. Percentage of cells with nuclear JAK2 
staining were quantified by counting five fields of view and displayed as mean  SEM for each treatment 
condition (n = 3). **P < 0.01, “ns” indicates not significant, P > 0.05. 
 
Figure 2. Inhibition of JAK2 alters oxidative damage-induced chromatin binding of MSH6 and 
DNMT1.  
(A) Chromatin affinity assays were performed using NCCIT cells untreated or treated with 100 M 
Tyrphostin AG490 for 6 hours followed by 30 min, 2 mM H2O2 treatment. Tight chromatin is the 
remaining protein in the chromatin pellet after extraction with 0.45 M NaCl buffer. Relative densitometry 
data are displayed as mean  SEM for each treatment condition (n=3). *P < 0.05, **P < 0.01, “ns” 
indicates not significant, P > 0.05. (B) NCCIT cells were untreated or treated with 2.2 nM BMS-911543 
for 6 hours followed by 30 min, 2 mM H2O2 treatment. Chromatin affinity assays and whole cell lysate 
extractions are performed. Relative densitometry data are displayed as meanSEM for each treatment 
condition (n = 3). *P < 0.05, **P < 0.01, “ns” indicates not significant, P > 0.05. (C) NCCIT cells were 
infected with nontarget (NT), or JAK2 shRNA lentiviral particles. After 96 h, they were untreated or 
treated with 2 mM H2O2 for 30 min. Chromatin affinity assays and whole cell lysate extractions were 
performed. Relative densitometry data are displayed as mean  SEM for each treatment condition (n = 3). 
*P < 0.05, **P < 0.01, “ns” indicates not significant, P > 0.05.   
 
Figure 3. JAK2 interacts with MSH2 and MSH6 in the nucleus after oxidative damage.  
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(A) NCCIT cells were untreated (U) or treated (T) with 2 mM H2O2 for 30 min. Co-IPs from cytoplasmic 
cellular fractions were performed with control IgG or anti-MSH2 antibodies. (B) Cells were treated as in 
A and Co-IPs from nuclear fractions were performed with control IgG or anti-JAK2 antibodies (C) Cells 
were treated as in A and nuclear Co-IPs were performed with control IgG or anti-MSH2 antibodies. (D) 
Cells were treated as in A and Co-IPs were performed with control IgG and anti-MSH6 antibodies. All 
above data are from one representative experiment of two biological replicates. 
 
Figure 4. Inhibiting JAK2 alters the PRC2 response to oxidative damage.  
(A) Chromatin affinity assays were performed using NCCIT cells untreated or treated with 100 M 
Tyrphostin AG490 for 6 hours followed by 30 min, 2 mM H2O2 treatment. * indicates EED2. Relative 
densitometry data are displayed as mean  SEM for each treatment condition for EZH2, SUZ12 and 
EED2 (n = 3). *P < 0.05, “ns” indicates not significant, P > 0.05. ND indicates signal is not detected. (B) 
Chromatin affinity assays were performed using NCCIT cells untreated or treated with 2.2 nM BMS-
911543 for 6 hours followed by 30 min, 2 mM H2O2 treatment. * indicates EED2. Relative densitometry 
data are displayed as mean  SEM for each treatment condition for EZH2, SUZ12 and EED2 (n = 3). *P 
< 0.05, *P < 0.01, “ns” indicates not significant, P > 0.05. ND indicates signal is not detected. (C) Whole 
cell lysate was collected from NCCIT cells infected with nontarget (NT), or JAK2 shRNA lentiviral 
particles for 96 h followed by 3 hour, 0.25 mM H2O2 treatment. Relative densitometry data are displayed 
as meanSEM for each treatment condition for H3K27me3 (n = 3). *P < 0.05, **P < 0.01, “ns” indicates 
not significant, P > 0.05. (D) SW480 cells were untreated or treated with 100 M Tyrphostin AG490 for 
6 hours followed by 3-hour, 0.5 mM H2O2 treatment. Total RNA was isolated and RT-qPCR is 
performed. Relative fold change displayed as mean  SEM of H2O2 treated over untreated (n = 3). *P < 
0.05, **P < 0.01. 
 
Figure 5. JAK2 expression is associated with CIMP status in human colorectal cancer.  
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 CIMP status and RNA-seq data were obtained from TCGA colorectal cancer database (COADREAD). 
One way ANOVA was used to test for statistical significance. The data are displayed as a box and 
whisker diagram showing 25th to 75th percentiles with the middle horizontal bar at the median. Whiskers 
are drawn using the Tukey method. (Cluster 3 and 4 are non-CIMP groups, RPKM indicates Reads Per 
Kilo base per Million.) **P < 0.01.  
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Figures 
 
Figure 1. Oxidative damage induces catalytic activity-dependent JAK2 nuclear localization. A
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Figure 2. Inhibition of JAK2 alters oxidative damage-induced chromatin binding of MSH6 and 
DNMT1.  
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Figure 3. JAK2 interacts with MSH2 and MSH6 in the nucleus after oxidative damage.  
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 Figure 4. Inhibiting JAK2 alters the PRC2 response to oxidative damage.  
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